article thumbnail

Pharma responds to proposed EU pharmaceutical legislation reform

European Pharmaceutical Review

Pinsent Masons Charlotte Weekes, Senior Associate at Pinsent Masons shared with EPR : “The Commission’s ambitious pharma legislation review is the first significant review of the European system since 2004.” “It "Our concern is that the pharma legislation is not there yet."

article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

Along their journey, specialty pharma patients interact with a series of siloed institutions: clinics, specialty pharmacies, copay program vendors, patient assistance programs, nurses, etc. Not unlike the financial industry, these institutions still exchange patient information via fax machines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A glance back to Pharma Integrates, London 2022 – part ii

pharmaphorum

Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022. It was a unique event, at which leaders from across the pharmaceutical pipeline addressed the needs of the industry, shared their own insights, and tackled debates on the crucial topics that influence the future of patient outcomes. Highly unlikely.”

Pharma 76
article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact.

Pharma 64
article thumbnail

Novel oral chemotherapeutic holds potential for stomach cancer patients

European Pharmaceutical Review

The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. New hope for stomach cancer patients.

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks. The pandemic raised the sector’s profile and has helped establish pharma as a desirable career path for several reasons, including job security, innovation, and societal value.

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

Nonetheless, some stakeholders remain concerned with this new approach given the complexity of biological medicines and the need for patients to be treated individually and have called for further discussions with regulators and all stakeholders. What are the concerns about the interchangeability of biosimilars? EMA Biosimilars Q&A.